Under the two-year research collaboration and license agreement, HiFiBiO will use its technology platforms to identify novel acute myeloid leukemia, or AML, targets and antibodies for Kite’s use in cell therapies.
HiFiBiO will receive an unspecified upfront payment and will be eligible for additional unspecified payments based on the achievement of certain research milestones, according to terms of the agreement, .
Kite Pharma was acquired by Foster City-based Gilead Sciences in August 2017 for $11.9 billion.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Tough Road Ahead for Insurance Renewals: What businesses can do to manage costs in an uncertain market
- Upfront Backs Glendale Cloud Security Firm
- Autry Museum President to Retire
- Paradigm's Pandemic Layoffs Become Permanent
- Rocket Lab Makes Successful Return to Flight
- American Moves Up Restart of LAX-to-Sydney Flight
- Gilead Sciences and Kite Pharma Acquire Cell Design Labs